CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
December 2013—Quest Diagnostics now offers BRCAvantage, a suite of four lab-developed genetic tests that identify mutations in BRCA1 and BRCA2 genes.
The BRCAvantage test is performed using next-generation sequencing and multiplex ligation-dependent probe amplification to detect all published deleterious mutations in BRCA1 and BRCA2. If a gene variant is identified, it is cross-referenced with mutational databases to promote reliable clinical interpretation. Quest also plans to support open access to patient-consented de-identified BRCA data to promote research and innovation in the field.
Concurrent with the introduction of BRCAvantage, Quest is underscoring its commitment to clinician education and to advancing appropriate use of BRCA testing.
Quest Diagnostics, 781-684-0770